TISSUE DONATION IS CRITICAL TO FIND TREATMENTS! Click here to learn more.
We envision a world where Epithelioid Hemangioendothelioma (EHE) is easily diagnosed and treatable. Join our dedicated community by subscribing to our emails.
EMPOWER YOURSELF WITH KNOWLEDGE
Upcoming Foundation Events
Quick Links
Patients
Community
Latest EHE News, Events and Research
The Pledge: Edition 42, Q3 – July-September, 2025
Publication of The Pledge quarterly newsletter is led by the EHE Rare Cancer Charity (UK). EHE patient advocacy groups from around the globe provide content including research news, patient and fundraising stories, and much more. Click here to view the most recent edition of the online EHE newsletter, The Pledge.
Read More
EHE Stabilization with Sirolimus: Results From POEM, a Prospective Multicentric Observational Study
Drs. Claudia Giani, Anna Maria Frezza, Silvia Stacchiotti, and colleagues from the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, and Royal Marsden Hospital, London, UK, presented results from POEM: a prospective observational study on Epithelioid Haemangioendothelioma at ESMO Congress 2025. The data presented included 57 consecutive molecularly confirmed EHE patients who entered the study, […]
Read More
Hanna Lab at Purdue University: ‘When cells in the body stop following the rules, cancer can take hold.’
You met Jason Hanna, PhD, at the 2025 EHE Global Patient Conference, where he highlighted work his lab is undertaking in EHE. We are thrilled to share a recent publication in Molecular Oncology from the Hanna Lab at Purdue University, highlighting their findings from a study focused on the YAP1-TFE3 subtype of EHE. The YAP1-TFE3 […]
Read More
Exciting Progress in EHE Research – Powered by Patients
We are thrilled to share a new publication, “EHE cell cultures are a platform for mechanistic and therapeutic investigation,” made possible by a partnership between the University of Iowa and the EHE Foundation. Under the leadership of Dr. Munir Tanas, Nicholas Scalora, PhD, and colleagues in the Tanas Lab sought to develop long-term EHE cell […]
Read More
Uniting for a Cure: A New Chapter in the Fight Against EHE
FOR IMMEDIATE RELEASE Hobart, WI – October 9, 2025 – The Center for Research and Analysis of VAscular Tumors (CRAVAT) Foundation has donated its resources to The EHE Foundation in a powerful alignment of vision and commitment to the people affected by epithelioid hemangioendothelioma (EHE) and the EHE scientific community. Founded in 2015 by Guy […]
Read More
Big Steve Day 2025: A Celebration of Life, Friendship, and Giving Back
On Saturday, June 28, 2025, more than 80 golfers, friends, and family gathered at Stony Creek Golf Course in Oak Lawn, Illinois, for the Third Annual Big Steve Day Golf Outing — a day filled with laughter, camaraderie, and purpose. This annual event honors the life and spirit of Steve Walsh, Jr., whose memory continues […]
Read More
Scientific & Medical Advisory Board Collaborates to Improve Outcomes for People Living with EHE
On September 10, 2024, The EHE Foundation held a virtual meeting of our Scientific & Medical Advisory Board (SMAB). The meeting aimed to welcome new members, review current research projects, and discuss future needs and goals to advance EHE research. The meeting began with a warm welcome to new members of the SMAB: Tom Chen, […]
Read More
GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and is Down-regulated by Sirolimus Through ATF4/ATF5 Suppression
Drs. Silvia Stacchiotti, Sandro Pasquali, and Nadia Zaffaroni (IRCCS – INT, Milan, Italy) and colleagues published their promising findings in Clinical Cancer Research, September 16, 2024. This study, funded in part by The EHE Foundation in partnership with EHE Rare Cancer Charity (UK), aimed to assess the efficacy of sirolimus for the treatment of EHE […]
Read More
Harnessing Cyclin-dependent Kinase Inhibitors to Gain Mechanistic Insight Into the Regulation of the TAZ-CAMTA1 Fusion Protein
Ajay Pobbati, PhD, Brian Rubin, MD, PhD, and colleagues at the Cleveland Clinic published their findings from the study “CDK9 inhibition by dinaciclib is a therapeutic vulnerability in epithelioid hemangioendothelioma” in Clinical Cancer Research, September 13, 2024. This study, funded in part by a grant from The EHE Foundation, provides a strong rationale for investigating […]
Read More